WASHINGTON -- Imaging agents currently in development that could detect the abnormal amyloid plaques in the brain associated with Alzheimer's disease and other dementias could help doctors diagnose these conditions, a Food and Drug Administration panel of medical experts said Thursday.
Such agents, which would be used in combination with positron-emission tomography scans, are designed to essentially "light up" areas of the brain that contain amyloid on imaging scans, but so far none are FDA approved. Beta-amyloid is a protein contained in clumps or plaques seen in the brains of people who have died of Alzheimer's complications.
While it is not entirely clear what role amyloid plays in Alzheimer's disease, most researchers believe it is... read this story
you may also be interested in this